• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

S53P4 生物活性玻璃支架在采用单阶段诱导膜技术治疗的骨干缺损中诱导 BMP 表达和整合性骨形成。

S53P4 bioactive glass scaffolds induce BMP expression and integrative bone formation in a critical-sized diaphysis defect treated with a single-staged induced membrane technique.

机构信息

Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Department of Musculoskeletal and Plastic Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

出版信息

Acta Biomater. 2021 May;126:463-476. doi: 10.1016/j.actbio.2021.03.035. Epub 2021 Mar 25.

DOI:10.1016/j.actbio.2021.03.035
PMID:33774197
Abstract

Critical-sized diaphysis defects are complicated by inherent sub-optimal healing conditions. The two-staged induced membrane technique has been used to treat these challenging defects since the 1980's. It involves temporary implantation of a membrane-inducing spacer and subsequent bone graft defect filling. A single-staged, graft-independent technique would reduce both socio-economic costs and patient morbidity. Our aim was to enable such single-staged approach through development of a strong bioactive glass scaffold that could replace both the spacer and the graft filling. We constructed amorphous porous scaffolds of the clinically used bioactive glass S53P4 and evaluated them in vivo using a critical-sized defect model in the weight-bearing femur diaphysis of New Zealand White rabbits. S53P4 scaffolds and standard polymethylmethacrylate spacers were implanted for 2, 4, and 8 weeks. Induced membranes were confirmed histologically, and their osteostimulative activity was evaluated through RT-qPCR of bone morphogenic protein 2, 4, and 7 (BMPs). Bone formation and osseointegration were examined using histology, scanning electron microscopy, energy-dispersive X-ray analysis, and micro-computed tomography imaging. Scaffold integration, defect union and osteosynthesis were assessed manually and with X-ray projections. We demonstrated that S53P4 scaffolds induce osteostimulative membranes and produce osseointegrative new bone formation throughout the scaffolds. We also demonstrated successful stable scaffold integration with early defect union at 8 weeks postoperative in critical-sized segmental diaphyseal defects with implanted sintered amorphous S53P4 scaffolds. This study presents important considerations for future research and the potential of the S53P4 bioactive glass as a bone substitute in large diaphyseal defects. STATEMENT OF SIGNIFICANCE: Surgical management of critical-sized diaphyseal defects involves multiple challenges, and up to 10% result in delayed or non-union. The two-staged induced membrane technique is successfully used to treat these defects, but it is limited by the need of several procedures and bone graft. Repeated procedures increase costs and morbidity, while grafts are subject to donor-site complications and scarce availability. To transform this two-staged technique into one graft-independent procedure, we developed amorphous porous scaffolds sintered from the clinically used bioactive glass S53P4. This work constitutes the first evaluation of such scaffolds in vivo in a critical-sized diaphyseal defect in the weight-bearing rabbit femur. We provide important knowledge and prospects for future development of sintered S53P4 scaffolds as a bone substitute.

摘要

临界尺寸骨干缺损复杂,存在固有愈合条件不佳的问题。自 20 世纪 80 年代以来,人们一直使用两阶段诱导膜技术来治疗这些具有挑战性的缺损。该技术涉及临时植入膜诱导间隔物和随后的骨移植物缺陷填充。单阶段、无移植物的技术将降低社会经济成本和患者发病率。我们的目标是通过开发一种强大的生物活性玻璃支架来实现这种单阶段方法,该支架可以替代间隔物和移植物填充。我们构建了临床使用的生物活性玻璃 S53P4 的非晶多孔支架,并在新西兰白兔承重股骨骨干的临界尺寸缺损模型中进行了体内评估。植入 S53P4 支架和标准聚甲基丙烯酸甲酯间隔物 2、4 和 8 周。通过 RT-qPCR 检测骨形态发生蛋白 2、4 和 7(BMPs),组织学证实诱导膜的形成,并评估其成骨刺激活性。使用组织学、扫描电子显微镜、能量色散 X 射线分析和微计算机断层扫描成像检查骨形成和骨整合。手动和 X 射线投影评估支架整合、缺损愈合和骨合成。我们证明 S53P4 支架可诱导成骨刺激膜,并在整个支架中产生骨整合的新骨形成。我们还证明了在植入烧结非晶 S53P4 支架的临界尺寸节段骨干缺损中,8 周术后早期即可成功稳定的支架整合和缺损愈合。这项研究为未来的研究提供了重要的考虑因素,并展示了 S53P4 生物活性玻璃作为大骨干缺损骨替代物的潜力。意义声明:临界尺寸骨干缺损的手术治疗涉及多个挑战,多达 10%的患者出现延迟愈合或不愈合。两阶段诱导膜技术成功地用于治疗这些缺损,但它受到需要多次手术和骨移植物的限制。重复手术增加了成本和发病率,而移植物会引起供体部位并发症和供应不足。为了将这种两阶段技术转化为无移植物的单一程序,我们开发了由临床使用的生物活性玻璃 S53P4 烧结而成的多孔非晶支架。这项工作首次在承重兔股骨的临界尺寸骨干缺损模型中对这种支架进行了体内评估。我们为未来烧结 S53P4 支架作为骨替代物的发展提供了重要的知识和前景。

相似文献

1
S53P4 bioactive glass scaffolds induce BMP expression and integrative bone formation in a critical-sized diaphysis defect treated with a single-staged induced membrane technique.S53P4 生物活性玻璃支架在采用单阶段诱导膜技术治疗的骨干缺损中诱导 BMP 表达和整合性骨形成。
Acta Biomater. 2021 May;126:463-476. doi: 10.1016/j.actbio.2021.03.035. Epub 2021 Mar 25.
2
Bone morphogenic protein expression and bone formation are induced by bioactive glass S53P4 scaffolds in vivo.生物活性玻璃 S53P4 支架在体内诱导骨形态发生蛋白表达和骨形成。
J Biomed Mater Res B Appl Biomater. 2019 Apr;107(3):847-857. doi: 10.1002/jbm.b.34181. Epub 2018 Sep 8.
3
Enriched mesoporous bioactive glass scaffolds as bone substitutes in critical diaphyseal bone defects in rabbits.富孔生物活性玻璃支架作为兔骨干大段骨缺损骨替代物。
Acta Biomater. 2024 May;180:104-114. doi: 10.1016/j.actbio.2024.04.005. Epub 2024 Apr 5.
4
Sintered S53P4 bioactive glass scaffolds have anti-inflammatory properties and stimulate osteogenesis in vitro.烧结的S53P4生物活性玻璃支架具有抗炎特性,并在体外刺激骨生成。
Eur Cell Mater. 2021 Jan 3;41:15-30. doi: 10.22203/eCM.v041a02.
5
Acellular dense collagen-S53P4 bioactive glass hybrid gel scaffolds form more bone than stem cell delivered constructs.无细胞致密胶原蛋白-S53P4生物活性玻璃混合凝胶支架比递送干细胞的构建体形成更多的骨组织。
Mater Sci Eng C Mater Biol Appl. 2021 Jan;120:111743. doi: 10.1016/j.msec.2020.111743. Epub 2020 Nov 21.
6
3D-printed, bioactive ceramic scaffold with rhBMP-2 in treating critical femoral bone defects in rabbits using the induced membrane technique.诱导膜技术联合 rhBMP-2 3D 打印生物活性陶瓷支架治疗兔股骨骨缺损
J Orthop Res. 2021 Dec;39(12):2671-2680. doi: 10.1002/jor.25007. Epub 2021 Feb 24.
7
Utilisation of bioactive glass S53P4 inside an induced membrane for severe bone defect with high risk of infection: a multi-center preliminary experience.生物活性玻璃 S53P4 在诱导膜内治疗感染高危严重骨缺损:多中心初步经验。
Injury. 2022 Oct;53 Suppl 2:S13-S19. doi: 10.1016/j.injury.2022.07.027. Epub 2022 Jul 17.
8
Evaluation of the clinical effectiveness of bioactive glass (S53P4) in the treatment of non-unions of the tibia and femur: study protocol of a randomized controlled non-inferiority trial.生物活性玻璃(S53P4)治疗胫腓骨骨不连的临床疗效评估:一项随机对照非劣效性试验的研究方案
Trials. 2018 May 30;19(1):299. doi: 10.1186/s13063-018-2681-9.
9
Mastoid obliteration and external auditory canal reconstruction using 3D printed bioactive glass S53P4 /polycaprolactone scaffold loaded with bone morphogenetic protein-2: A simulation clinical study in rabbits.使用负载骨形态发生蛋白-2的3D打印生物活性玻璃S53P4/聚己内酯支架进行乳突切除术和外耳道重建:兔模拟临床研究
Regen Ther. 2022 Oct 20;21:469-476. doi: 10.1016/j.reth.2022.09.010. eCollection 2022 Dec.
10
The Use of Bioactive Glass S53P4 as Bone Graft Substitute in the Treatment of Chronic Osteomyelitis and Infected Non-Unions - a Retrospective Study of 50 Patients.生物活性玻璃S53P4作为骨移植替代物治疗慢性骨髓炎和感染性骨不连——50例患者的回顾性研究
Z Orthop Unfall. 2018 Apr;156(2):152-159. doi: 10.1055/s-0043-124377. Epub 2018 Apr 17.

引用本文的文献

1
Assessment of Novel Boron-doped Mesoporous Bioactive Glass Nanoparticles Loaded Alginate Hydrogel in Dogs.新型硼掺杂介孔生物活性玻璃纳米颗粒负载藻酸盐水凝胶在犬类中的评估
Int Dent J. 2025 May 15;75(4):100828. doi: 10.1016/j.identj.2025.04.008.
2
Bioengineering strategies targeting angiogenesis: Innovative solutions for osteonecrosis of the femoral head.针对血管生成的生物工程策略:股骨头坏死的创新解决方案。
J Tissue Eng. 2025 Jan 24;16:20417314241310541. doi: 10.1177/20417314241310541. eCollection 2025 Jan-Dec.
3
Treatment of Bone Defects and Nonunion via Novel Delivery Mechanisms, Growth Factors, and Stem Cells: A Review.
通过新型递送机制、生长因子和干细胞治疗骨缺损与骨不连:综述
ACS Biomater Sci Eng. 2024 Dec 9;10(12):7314-7336. doi: 10.1021/acsbiomaterials.4c01279. Epub 2024 Nov 11.
4
A LDH-Derived Metal Sulfide Nanosheet-Functionalized Bioactive Glass Scaffold for Vascularized Osteogenesis and Periprosthetic Infection Prevention/Treatment.LDH 衍生金属硫化物纳米片功能化生物活性玻璃支架用于血管化骨生成和预防/治疗假体周围感染。
Adv Sci (Weinh). 2024 Oct;11(39):e2403009. doi: 10.1002/advs.202403009. Epub 2024 Aug 19.
5
In vitro and in vivo dissolution of biocompatible S59 glass scaffolds.生物相容性 S59 玻璃支架的体外和体内溶解。
J Mater Sci Mater Med. 2024 Jul 3;35(1):38. doi: 10.1007/s10856-024-06795-x.
6
Use of Autologous Bone Graft with Bioactive Glass as a Bone Substitute in the Treatment of Large-Sized Bone Defects of the Femur and Tibia.自体骨移植联合生物活性玻璃作为骨替代物治疗股骨和胫骨大尺寸骨缺损的应用
J Pers Med. 2023 Nov 24;13(12):1644. doi: 10.3390/jpm13121644.
7
Advanced Bioactive Glasses: The Newest Achievements and Breakthroughs in the Area.先进生物活性玻璃:该领域的最新成果与突破
Nanomaterials (Basel). 2023 Aug 9;13(16):2287. doi: 10.3390/nano13162287.
8
β-TCP/S53P4 Scaffolds Obtained by Gel Casting: Synthesis, Properties, and Biomedical Applications.通过凝胶浇铸法制备的β-磷酸三钙/S53P4支架:合成、性能及生物医学应用
Bioengineering (Basel). 2023 May 16;10(5):597. doi: 10.3390/bioengineering10050597.
9
3D-Printed PLA-Bioglass Scaffolds with Controllable Calcium Release and MSC Adhesion for Bone Tissue Engineering.用于骨组织工程的具有可控钙释放和间充质干细胞粘附功能的3D打印聚乳酸-生物玻璃支架
Polymers (Basel). 2022 Jun 13;14(12):2389. doi: 10.3390/polym14122389.
10
Enchondromas of the Hand: Curettage With Autogenous Bone Bioactive Glass S53P4 for Void Augmentation.手部内生软骨瘤:刮除术联合自体骨 53S 活性玻璃 P4 用于骨腔填充
In Vivo. 2022 May-Jun;36(3):1267-1273. doi: 10.21873/invivo.12826.